08:30 – 09:30
Round table 1A – The challenge of Low Vaccination Coverage Situation in Brazil and Worldwide
• Brazil – Ethel Maciel, SVS / Brazilian MoH*
• Americas – Jarbas Barbosa, PAHO*
• WHO – Samir Sodha, IVB/WHO*
Chair: Akira Homma, Fiocruz*
9:30–10:00
Coffee break
10:00–11:00
Round table 1B – How to overcome the low vaccination Coverage Challenges? Brazilian field experiences
• Creating connections with vulnerable groups – Oiapoque / Teatro Maiuhi, Elissandra Barros da Silva, Pet Indígena – Unifap*
• Strategies to reconquest the high vaccination coverages in Paraíba State, Renata Nóbrega, Health Surveillance Unit from Paraíba*
• For the Recovery of the High Vaccination Rates Project in Brazil through solidarity networks, Maria de Lourdes de Sousa Maia, PRCV Bio-Manguinhos*
11:00–11:30
Round table 1C – Challenges and perspectives for SUS to strengthen vaccination in Brazil
• Primary health care agenda, Ricardo Gadelha de Abreu, Secretary of Primary Health Care, Ministry of Health*
• Health surveillance agenda, Eder Gatti, Director, Department of Immunization and Preventable Diseases, Ministry of Health*
– Guided visit to the Museu da Vida and Fiocruz Castle
– Guided visit to Bio-Manguinhos’ vaccine and biopharmaceuticals production site
11:40 – 12:10 – Poster pitch
VACCINATION COVERAGE IN BRAZIL
• VAC-06 – Pertussis antibodies and vaccination coverage among healthcare professionals in Brazil is inadequate, Rita
Soares Barbosa Cardona, USP
• ORT-18- Human papillomavirus vaccination coverage in Brazilian North Region, 2013-2022, Mateus de Paula Von
Glehn, EpiSUS
• VAC-18 – Analysis of the possible factors associated with a low vaccination coverage among health Science
undergraduates, Camila Costa dos Santos, UFF
12:20 – 12:50 – Poster pitch
IMMUNE RESPONSE AND COVID-19
• VAC-09- Observational study of immunogenicity, effectiveness and reactogenicity in 6 months to 17 years age group
of vaccines against COVID-19, Camila Amormino Corsini, Fiocruz/Minas IRR
• IVD-06- New approaches in the detection of neutralizing antibodies using SARS-CoV-2 as a model, Caio Bidueira
Denani, Fiocruz/Bio-Manguinhos
• VAC-11 – Humoral immune response of allergic subjects vaccinated against COVID-19, Laura Alves Ribeiro Oliveira, Universidade Federal de Uberlândia
Coral da Fiocruz
▪ Carlos Augusto Grabois Gadelha, Brazilian MoH
▪ Mario Santos Moreira, Fiocruz
▪ Maurício Zuma, Bio-Manguinhos
▪ Akira Homma, Coordenador Científico do 7th ISI*
Poster Poster Oral Presentation 1 (VAC)
• VAC-03 – An alphavirus-derived replicon polyvalent RNA vaccine induces neutralizing antibodies in mice against omicron SARS-CoV-2 variant of concern, Vinicius Pinto Costa Rocha, SENAI CIMATEC
Poster Oral Presentation 2 (VAC)
• VAC-02 – Immunogenicity and protection evaluation of a live attenuated chimeric vaccine for zika virus in mice model,
José Henrique Rezende Linhares, Fiocruz/Bio-Manguinhos
14:40 – 15:10 – Poster pitch – VACCINOLOGY
• VAC-08 – Integrating Next-Generation Phage Display and bioinformatics approaches for the screening of B-cell epitopes of different antigens using polyclonal sera, Alexsander de Moraes, USP – Faculdade de Medicina de Ribeirão Preto
• VAC-07 – ntranasal Vaccinal strategy targeting mucosal surface for methicillin-resistant Staphylococcus aureus (MRSA) decolonization, Juliana Georg da Silva, Fiocruz/Bio-Manguinhos
• VAC-13 – Development and comparison of potential DNA and mRNA vaccines for Dengue serotype 2, Sarah Aparecida Rodrigues Sérgio, CT Vacinas – UFMG
New technologies for accelerating vaccine development and new delivery methods
• Adjuvants – Charles Lutsch, Sanofi*
• Vaccine development in 100 days – Ann-Muriel Steff, CEPI*
Chair: Sotiris Missailidis, Bio-Manguinhos
Vaccine hesitancy and the risk of polio re-emergence
• Causes of vaccine hesitancy, data from the study on low vaccine coverage and adverse effects, José Cassio de Moraes*
• Risk of Polio re-emergence in Brazil, Luiza Helena Falleiros*